

ASTRAZENECA PLC  
Form 6-K  
August 10, 2018

## **FORM 6-K**

# **SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**Report of Foreign Issuer**

**Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934**

**For the month of August 2018**

**Commission File Number: 001-11960**

## **AstraZeneca PLC**

**1 Francis Crick Avenue**

**Cambridge Biomedical Campus**

**Cambridge CB2 0AA**

**United Kingdom**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Edgar Filing: ASTRAZENECA PLC - Form 6-K

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If  Yes is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-

---

**AstraZeneca PLC (the Company )**

**Amended and Restated Articles of Association**

On 18 May, 2018, amended and restated Articles of Association were adopted at the Company's 2018 Annual General Meeting of Shareholders (the Articles of Association ). A copy of the Articles of Association is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The information contained in this report (including the exhibits hereto) is hereby incorporated by reference into the Company's Registration Statement on Form F-3, File No. 333-214756 and Forms S-8 (File No. 333-09062, No. 333-124689, No. 333-152767, No. 333-170381 and No. 333-216901).

**Exhibit List**

<b>Exhibit</b>	<b>Description</b>
99.1	<u>Articles of Association</u>

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: 10 August 2018

By:  
Name:  
Title:

AstraZeneca PLC  
  
/s/ Adrian Kemp  
Adrian Kemp  
Company Secretary